BHP Billiton Limited vs Zimmer Biomet Holdings Inc — how do they compare? BHP Billiton Limited trades at $90.27 (market cap $229.15B), while Zimmer Biomet Holdings Inc trades at $95.73 (market cap $18.55B). The key difference: BHP Billiton Limited is far larger — about 12.4× Zimmer Biomet Holdings Inc's market cap, and BHP Billiton Limited pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BHP | ZBH | |
|---|---|---|
Market Cap | $229.15B | $18.55B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $107.71 |
52-Week Low | $52.14 | $79.58 |
Enterprise Value | $243.35B | $25.61B |
Dividend Yield | 2.95% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.36, down 0.28% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q4 2025 earnings, missing EPS estimates, while Q2 2025 beat expectations. Revenue for 2024 was $55.66B with a net income margin of 18.97%, though profitability has fluctuated in recent years. Recent news highlights labor strikes at Port Hedland iron ore operations, potentially impacting production and revenue streams.
Outlook is cautious due to operational risks from strikes and volatile commodity prices, but strong cash flow and institutional buying support long-term value. Analysts are predominantly neutral with 65% hold ratings, reflecting balanced risk-reward. Key risks include labor disputes and copper output misses, while opportunities lie in AI-driven copper demand growth and cost management.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →